GLUE

NASDAQ Healthcare

Monte Rosa Therapeutics, Inc. - Common Stock

Biotechnology

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1a, IL-1รŸ and IL-18, as well as damage-associated molecular patterns. In addition, it develops CDK2 to treat multiple cancers, including ovarian, endometrial, gastric and breast. Further, its pipeline includes programs in immunology and inflammation indications, oncology, cardiovascular, metabolic, and genetic diseases. The company also develops QuEEN, a discovery engine, to enable its target-centric MGD discovery and development approach and its rational design of MGD product candidates. It has a strategic collaboration and licensing agreement with F. Hoffmann-La Roche Ltd.; and Novartis. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

๐Ÿ“Š Market Data
Price$18.80
Volume631,678
Market Cap1.50B
Beta1.640
RSI (14-Day)59.5
200-Day MA$13.61
50-Day MA$17.69
52-Week High$25.77
52-Week Low$3.51
Forward P/E-11.06
Price / Book5.29
๐ŸŽฏ Investment Strategy Scores

GLUE scores across each investment strategy. Higher is better for that strategy's goals.

High dividend yield + low volatility
๐Ÿš€ Moon Shot 82/100โ–ฒ +1
High growth potential (high beta + oversold)
๐Ÿ”ช Falling Knife 16/100โ–ฒ +3
Contrarian plays (oversold + below moving average)
๐ŸŽˆ Over-Hyped 60/100โ–ผ -5
Overbought stocks (potential short candidates)
Large-cap, institutional-quality stocks
๐Ÿ” Strategy Interpretation

Best fit: ๐Ÿš€ Moon Shot (82/100) โ€” this strategy High growth potential (high beta + oversold).

Lowest fit among scored strategies: ๐Ÿ’ฐ Dividend Daddy (11/100). No single score is a buy or sell signal โ€” use multiple lenses together. Learn how to read these scores โ†’

Find GLUE in your text

Paste any article, transcript, or post โ€” the tool will extract GLUE and every other hidden ticker.

Try the Ticker Extractor โ†’

Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-05-01.